Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Somatostatin analogues in treatment-refractory meningioma: a systematic review with meta-analysis of individual patient data

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. The role of systemic inflammatory cells in meningiomas

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Quality assessment of evidence must be stated in conclusions to avoid conveying questionable recommendations

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  1. Loss of H3K27me3 in WHO grade 3 meningioma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Treatment-refractory meningiomas have a dismal prognosis and limited treatment options. Meningiomas express high-densities of somatostatin receptors (SSTR), thus potentially susceptible to antitumorigenic effects of somatostatin analogues (SSA). Evidence for SSA in meningiomas is scarce, and it is unclear if published literature would either (1) support wider use of SSA, if (2) more evidence is desirable, or if (3) available evidence is sufficient to discard SSA. We addressed the need for more evidence with a systematic review and meta-analysis. We performed an individual patient data (IPD) meta-analysis. Main outcomes were toxicity, best radiological response, progression-free survival, and overall survival. We applied multivariable logistic regression models to estimate the effect of SSA on the probability of obtaining radiological disease control. The predictive performance was evaluated using area under the curve and Brier scores. We included 16 studies and compiled IPD from 8/9 of all previous cohorts. Quality of evidence was overall ranked "very low." Stable disease was reported in 58% of patients as best radiological response. Per 100 mg increase in total SSA dosage, the odds ratios for obtaining radiological disease control was 1.42 (1.11 to 1.81, P = 0.005) and 1.44 (1.00 to 2.08, P = 0.05) for patients treated with SSA as monodrug therapy vs SSA in combination with everolimus, respectively. Low quality of evidence impeded exact quantification of treatment efficacy, and the association between response and treatment may represent reverse causality. Yet, the SSA treatment was well tolerated, and beneficial effect cannot be disqualified. A prospective trial without bias from inconsistent study designs is warranted to assess SSA therapy for well-defined meningioma subgroups.

OriginalsprogEngelsk
TidsskriftNeurosurgical Review
Vol/bind45
Udgave nummer5
Sider (fra-til)3067-3081
Antal sider15
ISSN0344-5607
DOI
StatusUdgivet - okt. 2022

Bibliografisk note

© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

ID: 80383232